APLS Apellis Pharmaceuticals Inc

Price (delayed)

$49.83

Market cap

$3.77B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.76

Enterprise value

$3.73B

Sector: Healthcare
Industry: Biotechnology

Highlights

The company's debt has surged by 142% YoY and by 2.9% QoQ
APLS's net income has dropped by 135% year-on-year and by 14% since the previous quarter

Key stats

What are the main financial stats of APLS
Market
Shares outstanding
75.74M
Market cap
$3.77B
Enterprise value
$3.73B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
35.59
Price to sales (P/S)
5,833.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5,774.05
Earnings
Revenue
$646,000
EBIT
-$512.1M
EBITDA
-$511.3M
Free cash flow
-$389.41M
Per share
EPS
-$7.76
Free cash flow per share
-$5.15
Book value per share
$1.4
Revenue per share
$0.01
TBVPS
$10.16
Balance sheet
Total assets
$768.33M
Total liabilities
$662.49M
Debt
$372.88M
Equity
$105.84M
Working capital
$667.08M
Liquidity
Debt to equity
3.52
Current ratio
9.86
Quick ratio
9.69
Net debt/EBITDA
0.09
Margins
EBITDA margin
-79,149.3%
Gross margin
100%
Net margin
-83,027.3%
Operating margin
-69,637.3%
Efficiency
Return on assets
-79%
Return on equity
-339.9%
Return on invested capital
-101.8%
Return on capital employed
-73.9%
Return on sales
-79,272.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

APLS stock price

How has the Apellis Pharmaceuticals stock price performed over time
Intraday
-5.09%
1 week
-4.15%
1 month
-5.68%
1 year
23.04%
YTD
-12.88%
QTD
-12.88%

Financial performance

How have Apellis Pharmaceuticals's revenue and profit performed over time
Revenue
$646,000
Gross profit
$646,000
Operating income
-$449.86M
Net income
-$536.36M
Gross margin
100%
Net margin
-83,027.3%
APLS's net income has dropped by 135% year-on-year and by 14% since the previous quarter
APLS's operating income has dropped by 105% year-on-year and by 15% since the previous quarter

Growth

What is Apellis Pharmaceuticals's growth rate over time

Valuation

What is Apellis Pharmaceuticals stock price valuation
P/E
N/A
P/B
35.59
P/S
5,833.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5,774.05
The EPS has dropped by 107% year-on-year and by 10% since the previous quarter
The equity has dropped by 54% since the previous quarter and by 24% year-on-year
The P/B is 46% more than the last 4 quarters average of 24.3

Efficiency

How efficient is Apellis Pharmaceuticals business performance
APLS's ROE has shrunk by 155% YoY and by 20% QoQ
The company's return on invested capital has surged by 77% YoY and by 16% QoQ
APLS's ROA is down by 13% year-on-year

Dividends

What is APLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for APLS.

Financial health

How did Apellis Pharmaceuticals financials performed over time
Apellis Pharmaceuticals's total assets is 16% more than its total liabilities
APLS's total liabilities has surged by 103% year-on-year and by 3.8% since the previous quarter
Apellis Pharmaceuticals's total assets has soared by 65% YoY but it has decreased by 12% from the previous quarter
The company's debt has surged by 142% YoY and by 2.9% QoQ
The equity has dropped by 54% since the previous quarter and by 24% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.